{"id":"W2587327379","doi":"10.1093/annonc/mdx008","title":"Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":235,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Merck","keywords":"Medicine; Pembrolizumab; Oncology; Lung cancer; Internal medicine; First line therapy; Phases of clinical research; Clinical trial; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001174784,0.001437608,0.001896311,0.0003741209,0.0004857264,0.001304748,0.0006993715,0.001416371,0.003317701],"category_scores_gemma":[0.000854666,0.0004795189,0.001557762,0.0002914884,0.000708761,0.00141103,0.000302172,0.004228241,0.0009311586],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001172007,"about_ca_system_score_gemma":0.001142352,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007891433,"about_ca_topic_score_gemma":0.002404194,"domain_scores_codex":[0.9997576,0.00008722558,0.000009363568,0.00005342336,0.00002125645,0.00007116701],"domain_scores_gemma":[0.999649,0.00006693951,0.00005483383,0.0000213254,0.00002138143,0.0001865169],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7161327,0.03747612,0.004886288,0.002033066,0.002636536,0.0003044717,0.0003598919,0.00354718,0.02469372,0.0005755596,0.01004908,0.1973054],"study_design_scores_gemma":[0.8282365,0.1541018,0.007828101,0.0001098351,0.0009171889,0.0003015933,0.00009066171,0.001600841,0.00203104,0.0004458714,0.004301022,0.00003564174],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9826658,0.008485662,0.0005189504,0.001928102,0.0004260671,0.001900011,0.001158561,0.0001188227,0.002798102],"genre_scores_gemma":[0.9837551,0.005827046,0.001323411,0.001888746,0.0002281606,0.001921423,0.001800463,0.00003246202,0.003223148],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003317701,"threshold_uncertainty_score":0.01109886,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04446429030586001,"score_gpt":0.4057339487908878,"score_spread":0.3612696584850277,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}